by Harvey Mogojwe | Sep 1, 2021
For every thousand children born in Zambia, 61 will die before their fifth birthday – almost twice the global rate. The leading causes of death include pre-term birth complications, birth asphyxia and trauma, pneumonia, congenital anomalies, diarrhea, and malaria, all...
by Corina Milic | Aug 25, 2021
The report provides market intelligence on hepatitis C (HCV) diagnostics and drugs in low- and middle-income countries to help guide elimination of the disease. It also covers preliminary insights into the hepatitis B (HBV) market. We are pleased to release the second...
by Corina Milic | Aug 16, 2021
CHAI is pleased to share news today from MedAccess of measures to increase access to a patient-friendly preventative therapy for tuberculosis (TB). The volume guarantee agreement between MedAccess and Macleods Pharmaceuticals, in partnership with CHAI and...
by Corina Milic | Aug 12, 2021
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI. Please tell us a bit about your background and what brought you to CHAI. I grew up in France and studied veterinary medicine there. I have always been fascinated by...
by Harvey Mogojwe | Aug 5, 2021
TB program point-of-care testing was leveraged for HIV viral load and early infant diagnosis testing. Many national testing and treatment programs have traditionally been “vertical” in nature – focused on one disease alone – and have relied on processing tests in...
by Scott Miller | Aug 4, 2021
We were shocked and saddened to learn today that CHAI’s Board Chair, Dr. Tachi Yamada, has passed away. Tachi has been a driving force in global health for decades and his loss will be felt around the world. As a physician, professor, mentor, and leader of large and...
by Harvey Mogojwe | Aug 3, 2021
In 2011, the HPTN 052 trial demonstrated that people living with HIV who initiated treatment earlier – also referred to as early access to antiretroviral therapy (ART) for all – were less likely to transmit the virus to partners. Adoption of this approach meant that...
by Corina Milic | Jul 27, 2021
Hepatitis B (HBV) is an incurable liver infection that can lead to severe health consequences including liver failure and liver cancer. It is a silent killer – most people do not experience any symptoms when they get infected and children in particular are less able...
by Harvey Mogojwe | Jul 27, 2021
Hepatitis C (HCV) affects more than 58 million people worldwide, and a significant number of people with the disease will progress to chronic disease, liver cancer, and death. Although HCV is curable in more than 95 percent of patients with direct-acting antivirals...
by Corina Milic | Jul 25, 2021
Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announce pricing agreement with pharmaceutical company Hetero Labs LTD to make available generic version of best-in-class second-line therapy for people living with HIV. July 26, 2021 – Unitaid and CHAI...
